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Cellular ornithine biosynthesis could be expected to play a significant role in putrescine formation and 
hence in growth. Two enzymes are involved in ornithine biosynthesis: arginase and transamidinase. These 
enzyme activities were studied in two human melanoma cell lines differing in their K, of diamine oxidase 
for putrescine and in their tumorigenicity in nude mice. Arginase activity accounts for the majority of 
ornithine formed in the highly tumorigenic cell line, while the majority of ornithine is derived from 
transamidinase action in the poorly tumorigenic cell line, with concomitant formation of methyl guani- 
dine, a potent inhibitor of diamine oxidase. 
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1. INTRODUCTION 
It is now well documented that increases in poly- 
amines occur in cell growth processes [l-3]. L- 
Ornithine decarboxylase (L-ornithine carboxyl- 
lyase, EC 4.1.1.17) (ODC) catalyses the formation 
of putrescine from L-ornithine, and a large body 
of experimental evidence points to the key role of 
this enzyme ODC as the rate limiting step in the 
biosynthetic pathway of the polyamines. a-Difluo- 
romethylomithine (DFMO) has been shown to 
represent a highly selective, enzyme-activated, in- 
hibitor of ODC, resulting in the depletion of intra- 
cellular putrescine and spermidine content in sev- 
eral mammalian systems, with concomittant arrest 
of cell proliferation ]4]. In view of this, cellular 
ornithine biosynthesis could be expected to play a 
significant role in putrescine formation and hence 
in growth. Two enzymes are involved in ornithine 
biosynthesis: arginase (L-arginine amidohydro- 
lase, EC 3.5.3.1.) which catalyses the cleavage of 
L-arginine to urea and ornithine, and transamidin- 
ase (L-arginine-glycine amidinotransferase, EC 
2.1.4.1) which transfers an amidine group from ar- 
ginine to glycine to form guanidinoacetate and or- 
nithine. Elevated arginase activities have been 
demonstrated in growing tissues and tumours [S- 
81, but this increased arginase activity has not al- 
ways paralleled increased ODC activity [9]. It 
therefore seemed important to determine the con- 
tribution of transamidinase to omithine biosyn- 
thesis under such conditions, especially as the 
other product of transamidinase action is guanidi- 
noacetate which can be decarboxylated, at least 
theoretically, to methyl guanidine a potent inhibi- 
tor of diamine oxidase activity [lo], and that 
alteration in diamine oxidase activity due to an 
altered K,,, of the enzyme for putrescine takes 
place in tumorigenic human melanoma cells [ 111. 
Arginase and transamidinase activities were 
studied in 2 human melanoma cell lines differing 
in their K, of diamine oxidase and in their tu- 
morigenicity in nude mice. This communication 
reports that arginase activity is the major contribu- 
tion to ornithine formation in the highly tu- 
morigenic cell line while the majority of omithine, 
leading to greater formation of methyl guanidine, 
would appear to be derived from transamidinase 
action in the poorly tumorigenic ell line. 
2. MATERIALS AND METHODS 
L-[guanido-‘4C]Arginine-HC1 (56 mCi/mmol) 
was obtained from the Amersham International 
Published by Elsevier Biomedical Press 
00145793/82/0000-0000/$2.75 0 1982 Federation of European Biochemical Societies 63 
Volume 148, number 1 FEBS LETTERS November 1982 
(Bucks) and was purified as in [ 121. 
L-Arginine-HCl and L-glycine were purchased 
from Sigma Chemical Co. (St Louis MO). 
Two achromic cell strains MJDau and MrDor, 
derived from metastatic human malignant melano- 
ma were used. MjDau cells are highly tumorigenic 
in nude mice, while MtDor cells are poorly 
tumorigenic [13]. The homogenates for enzymic 
assays were obtained from cells in tissue culture as 
in [ 111. 
Arginase activity in 2 human melanoma cell lines. 
Cellular extracts were incubated for 120 min at 37°C at 
pH 9.7 in 250 ~1. [guanido-‘4C]Arginine was diluted with 
unlabeled arginine to a constant spec. act. of 5 pCi/ 
mmol. [‘4C]Urea released was determined as in 1121. 
[‘4C]Urea formed in: (+)M,Dau; (v)MrDor. 
Arginase activity was determined at pH 9.7 by 
the radiometric assay developed in [ 121. 
Transamidinase activity was determined by 
measuring 
I 
t4C]guanidinoacetate produced from 
L-[guanido- 4C]arginine. The 250 ~1 incubation 
volume contained 100 mM potassium phosphate 
buffer (pH 7.4) 25 mM L-arginine, 75 mM glycine, 
I mg cellular extract, and was incubated at 37°C 
for 120 min. The reaction was stopped by adding 
50 ~1 100% trichloroacetic acid. The mixture was 
then poured onto a (20 x 1 cm) column tilled with 
Dowex 5OW-X8 (100-200 mesh, H+form). [14C]- 
Urea, in contrast to [‘4C]guanidinoacetate, [ 14C]- 
methyl guanidine and L-[guanido-‘4C]arginine is 
not retained by Dowex 5OW-X8 (H+) and can 
therefore be collected directly into scintillation 
vials. [14C]Guanidinoacetate and [ 14C]methyl 
guanidine were eluted from the resin with 40 ml 
2 N HCI, L-[guanz’do-14C]arginine with 20 ml 6 N 
HCl. The 2 N HCl fraction was taken to dryness 
on a rotary evaporator, the residue was dissolved 
in water, readjusted to pH 2.5 and applied onto a 
Dowex 5OW-X8 (H+) column, [‘4C]guanidinoace- 
tate and [ 14C]methyl guanidine were successively 
eluted from the resin with 50 ml of a linear gra- 
dient of 0.5-2.0 N HCl. 
Identification of each fraction was performed by 
comparison of the Rf of unknown with that of au- 
thentic markers by thin-layer chromatography on 
silica gel using as solvent n-butanollacetonelgla- 
cial acetic acid/water (35:35: 10:20, by vol.) [14]. 
The position of the authentic compounds was re- 
vealed by the Voges-Proskauer reaction [ 151 that of 
the labelled unknowns by determining the radioac- 
tive content of 1 cm fractions of the thin-layer 
plate. 
3. RESULTS 
3.1. A rginase activity in melanoma cell lines 
To determine whether differences in arginase 
activity exist between M3Dau and MtDor cell 
lines, the activity of this enzyme was measured on 
homogenates derived from cells at confluence. The 
activity of arginase in melanoma cells was higher 
in M,Dau cells than in MrDor cells at different 
substrate concentrations (fig. 1). These differences 
are not due to different localization of arginase 
because the assay are carried on whole cellular 
extract. Given that even at the optimum pH for 
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Table 1 
Arginase and transamidinase activities in two achromic melanoma cell lines 
Melanoma pH in assay [ 14C]Urea formed [ “C]Guanidinoacetate 
cell lines solution (pm01 . mg protein-’ . hh’) formed (pmol . mg protein-’ . hh’) 
M3Dau 9.7 657 + 306 72+ 12 
M ,Dor 9.7 88k 47 1132 79 
M,Dau 7.4 111+ 42 2112144 
M ,Dor 7.4 382 12 249 + 143 
The results are mean + SEM of 5 replicates 
arginase a small but significant amount of [14C]- 
guanidine is used up via transamidination, the 
amount of [ t4C]guanidinoacetate formed under 
conditions o 
90% of the [ 74 
timal for arginase was determined.’ 
Clguanidine group of arginine was 
found in urea while 10% is recovered in guanidino- 
acetate from M3Dau cells while there was about an 
equal distribution of radioactivity in urea and gua- 
nidinoacetate from M1Dor cells (table 1). 
3.2. Transamidinase activity in melanoma cell lines 
These results prompted us to investigate directly 
transamidinase activity under optimal conditions 
and to assess any loss of [14C]guanidine via re- 
sidual arginase action. Transamidinase activity in 
M3Dau cells and in M1Dor cells is not significantly 
different (table 1) whereas loss of [14C]guanidine 
through urea (arginase action) is 3-fold greater 
(PC 0.05) in M3Dau than in MtDor. 
In view of residual enzyme activity of trans- 
amidinase when arginase is determined in optimal 
conditions and vice versa, the total contribution of 
[guanido-‘4C]arginine to [ 14C]guanidinoacetate 
formation and to [‘4C]urea formation was assessed 
at both pH-values. Table 2 shows that for MsDau 
cells 73.1% of L-[guanido-14C]arginine is metabo- 
Table 2 
Contribution of arginase and transamidinase to 
ornithine biosynthesis in two melanoma cell lines 
Melanoma Total Arginase Transamidin- 
cell lines act.a act. (W) ase act. (W) 
MsDau 105 1 73.1 26.9 
M,Dor 488 25.8 74.2 
a(pmol [ 14C]guanidinoacetate+ [ 14C]Urea . mg protein-t. h-1) 
lized via arginase and 26.9% via transamidinase 
whereas for M1Dor cells these values are 25.8% 
and 74.2%, respectively. Thus in M3Dau cells high- 
ly tumorigenic in nude mice, ornithine is appar- 
ently synthetized preferentially by the arginase 
pathway while in MtDor the poorly tumorigenic 
line, the transamidinase pathway is predominant. 
3.3. Separation and identification of labelled reac- 
tion products of transamidinase activity 
Guanidinoacetate can be theoretically decar- 
boxylated to methyl guanidine, a potent inhibitor 
of diamine oxidase [lo]. It was therefore of interest 
to determine whether methyl guanidine was for- 
med under the incubation conditions described. 
Accordingly, the reaction products were separated 
by column chromatography on Dowex 5OW-X8 
(H+form) in 2 steps and identified as in section 2. 
Table 3 shows that the amount of [14C]methyl 
guanidine formed is greater in MtDor cells than in 
MjDau cells. The identity in Rf was verified in 
another solvent system: isopropanol/formic acid/ 
water (80:4:20, by vol.). 
4. DISCUSSION 
It appears from these results that omithine can 
be derived in these two human melanoma cell 
lines through the action of both arginase and 
transamidinase. However, the contribution of 
these enzymes to ornithine biosynthesis may differ 
in these cell lines. Thus, arginase activity is 7.5-fold 
greater in MjDau than in MlDor, but, their trans- 
amidinase activity is roughly equivalent. 
A net preference for the arginase pathway in 
M3Dau cells is seen at pH 9.7 and is further evi- 
denced at pH 7.4, the optimal pH for transamidi- 
65 
Volume 148, number 1 FEBSLETTERS November 1982 
Table 3 
Methyl guanidine formation from guanidinoacetate in 
melanoma cell lines 
Melanoma Methyl guanidine 
cell lines (X formation) 
M3Dau 44.1Ok4.6 (3) 
MtDor 93.72 f 2.5 (3) 
Mean + SE; data represent the average of 
3 determinations 
nase, where the residual arginase activity contrib- 
utes to the formation of 111 pmol urea, i.e., due to 
the stoichiometry of the reaction, 34% of the or- 
nithine formed. 
However, the residual transamidinase activity 
which is still manifest at pH 9.7 contributes to 
form 113 pmol guanidinoacetate in MtDor cells. 
These 113 pmol guanidinoacetate are roughly 
equivalent to the amount of urea and hence to the 
amount of ornithine formed at pH 9.7. This indi- 
cates that in this cell line, even under conditions 
optimal for arginase activity, about half of the or- 
nithine is formed through the transamidinase 
pathway. Thus, regardless of whether the assays 
are performed under optimal pH conditions, it 
seems reasonable to conclude that arginase activity 
is the major contribution to ornithine formation in 
M,Dau cells, while the majority of ornithine in 
M1Dor cells would appear to be derived from 
transamidinase action. This difference in arginine 
metabolism between the two cell lines is illustrated 
on table 2. 
Another way of expressing this different utiliza- 
tion of arginine between these 2 cell lines is the 
guanidinoacetate/urea action under optimal con- 
ditions. In MjDau this ratio is 0.3 while in M1Dor 
it is -3, a IO-fold difference: this ratio is of the 
same order of magnitude as that obtained for these 
2 cell lines in culture in arginine-deprived medium 
to which L-[guanido-14C]arginine was added (not 
shown). 
Guanidinoacetate, the other product of trans- 
amidinase action, is not metabolically inert. In fact 
the possibility of its subsequent decarboxylation to 
methyl guanidine was verified in these 2 cell lines. 
In MtDor methyl guanidine formation accounted 
for 93.72% of the metabolites formed from guani- 
66 
dinoacetate, while in M3Dau methyl guanidine ac- 
counted for only 44.10% of the metabolites formed 
from guanidinoacetate. Since methyl guanidine 
has been shown to be an inhibitor of diamine ox- 
idase [lo], the decreased activity of this enzyme in 
MlDor reported in [l l] may be due to the in- 
creased production of methyl guanidine through 
this pathway. 
The verification of this relationship should 
provide an approach for directly testing the effect 
of methyl guanidine on the tumorigenicity of 
human melanoma cells. 
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